EAM Investors LLC grew its stake in Immunomedics, Inc. (NASDAQ:IMMU) by 270.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 507,114 shares of the biopharmaceutical company’s stock after purchasing an additional 370,086 shares during the period. Immunomedics comprises about 0.7% of EAM Investors LLC’s investment portfolio, making the stock its 14th biggest position. EAM Investors LLC owned about 0.46% of Immunomedics worth $4,478,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Geneva Advisors LLC grew its position in Immunomedics by 0.6% in the 2nd quarter. Geneva Advisors LLC now owns 31,635 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 200 shares during the last quarter. Amalgamated Bank grew its position in Immunomedics by 8.1% in the 2nd quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 966 shares during the last quarter. Legal & General Group Plc grew its position in Immunomedics by 7.4% in the 2nd quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 1,747 shares during the last quarter. Creative Planning grew its position in Immunomedics by 1.7% in the 2nd quarter. Creative Planning now owns 179,130 shares of the biopharmaceutical company’s stock worth $1,582,000 after purchasing an additional 3,065 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in Immunomedics by 2.1% in the 1st quarter. Teachers Advisors LLC now owns 189,537 shares of the biopharmaceutical company’s stock worth $1,226,000 after purchasing an additional 3,876 shares during the last quarter. Institutional investors own 77.99% of the company’s stock.

Several analysts have issued reports on the stock. Jefferies Group LLC set a $11.00 price target on shares of Immunomedics and gave the stock a “buy” rating in a research report on Thursday, August 17th. BidaskClub lowered shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Zacks Investment Research lowered shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Cowen and Company restated an “outperform” rating and issued a $15.00 price target on shares of Immunomedics in a research report on Monday, July 24th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $13.00.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/24/immunomedics-inc-immu-shares-bought-by-eam-investors-llc.html.

Shares of Immunomedics, Inc. (NASDAQ:IMMU) traded up 0.17% during mid-day trading on Friday, hitting $11.47. 1,852,703 shares of the stock traded hands. The company’s 50 day moving average is $10.09 and its 200 day moving average is $7.94. The firm’s market capitalization is $1.28 billion. Immunomedics, Inc. has a one year low of $2.02 and a one year high of $12.96.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings data on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.13). The firm had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.75 million. Immunomedics’s revenue for the quarter was down 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, equities analysts expect that Immunomedics, Inc. will post ($0.53) EPS for the current fiscal year.

In other news, insider David M. Goldenberg sold 20,000 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $12.64, for a total value of $252,800.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Cynthia L. Goldenberg sold 40,000 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $10.72, for a total transaction of $428,800.00. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock worth $1,051,200 over the last three months. Insiders own 6.60% of the company’s stock.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.